Scotland’s ProStrakan Group has acquired the outright worldwide rights for two of its leading products – Rectogesic (glyceryl trinitate), an ointment for chronic anal fissures, and Tostran (testosterone gel) – from US-based partner Cellegy Pharmaceuticals.
ProStrakan has paid $9 million to get the rights on a royalty and milestone-free basis and inherits existing commercial licences for certain southeast Asian and other countries. It also owns Cellegy’s related patent estate and other intellectual property.
The company said that it is “actively planning the necessary additional clinical work for both products” in order to secure approvals in the USA.
Wilson Totten, ProStrakan’s chief executive, said the two products “are high-potential, high-value specialist care opportunities and form a very exciting platform on which to establish a commercial presence in the USA.”
